Kennedy Institute Early Arthritis KIR 2000 Study
- Date:
- 1999-2006
- Reference:
- SA/KET/A/1/8
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Comprises records relating to the Placebo controlled Kennedy Institute and Charing Cross Hospital led study "Assessment of Joint Inflammation and Structured Damage in Predicting Patient Response to Treatment of Early Rheumatoid Arthritis with Methotrexate Monotherapy or Combined Anti-TNFalpha and Methotrexate Combination Therapy."
The study included c.24 patients and ran for three core years followed by post study patient follow-up. The study aimed to compare two different approaches to the treatment of rheumatoid arthritis (methotrexate alone or Anti-TNFalpha and methotrexate in combination). It also aimed to identify whether infliximab treatment should be initiated early in the evolution of rheumatoid arthritis before joint destruction becomes irreversible. The study used advancements in imaging technologies to assess the erosion of joins and the impact of infliximab (cA2) on patient's joints. The investigators of the study included Ravinder Maini, Dr Peter Taylor, and Dr Alan Steuer and the study used one site, largely facilitated by Charing Cross Hospital.